-

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2024 financial results after the close of the U.S. financial markets on February 19, 2025. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.

Fourth quarter 2024 webcast & conference call details

Date: 

 

Wednesday, February 19, 2025

Time: 

 

5 p.m. ET

Webcast: 

 

The live webcast can be accessed at www.exactsciences.com

Telephone: 

 

Domestic callers, dial 888-330-2384 

 

 

International callers, dial +1 240-789-2701

           

 

Access code for both domestic and international callers: 4437608

 A replay of the webcast will be available at www.exactsciences.com. The webcast, conference call, and replay are open to all interested parties.

About Exact Sciences Corp.

A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard® and Oncotype® tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. For more information, visit ExactSciences.com, follow Exact Sciences on X @ExactSciences, or find Exact Sciences on LinkedIn and Facebook.

Contacts

Erik Holznecht
Exact Sciences Corp.
investorrelations@exactsciences.com
608-800-6605

Industry:

Exact Sciences Corp.

NASDAQ:EXAS
Release Versions
English

Contacts

Erik Holznecht
Exact Sciences Corp.
investorrelations@exactsciences.com
608-800-6605

More News From Exact Sciences Corp.

Exact Sciences Applauds Passage of Legislation Establishing Medicare Coverage Pathway for Multi-Cancer Early Detection Tests

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with s...

Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: more than two million breast cancer patients worldwide have now used the test to help guide treatment decisions. Backed by more than two decades of clinical evidence, the test has become a global standard-of-care by identifying patients who are – and are not – likely t...

Exact Sciences, the NSABP Foundation, and the German Breast Group Present Results for the Oncodetect® MRD Test in Early Triple-Negative Breast Cancer at SABCS

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG), demonstrated that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early...
Back to Newsroom